Pharmaceutical care for patients with breast and ovarian cancerReport as inadecuate




Pharmaceutical care for patients with breast and ovarian cancer - Download this document for free, or read online. Document in PDF available to download.

Supportive Care in Cancer

, Volume 20, Issue 11, pp 2669–2677

First Online: 02 February 2012Received: 13 August 2011Accepted: 08 January 2012

Abstract

PurposeIndividualized patient care may help reduce the incidence of adverse drug events in systemic cancer therapy. This study was conducted to explore the feasibility and potential of additional pharmaceutical care for breast and ovarian cancer patients.

MethodsThe study was designed as a prospective, multicentered cohort study with a control group. Ninety-eight breast or ovarian cancer patients were recruited from outpatient oncology clinics and primary care oncologists: initially into the control group receiving standard care and after implementation of pharmaceutical care into the intervention group consisting of additional patient counseling on the management of treatment-associated adverse events and optimization of supportive medication. Primary outcome was the complete response to the antiemetic prophylaxis. Secondary endpoints were the severity of nausea, frequency of emesis, health-related quality of life, and patient satisfaction with information on cancer treatment education.

ResultsForty-eight patients were included in the control group and 50 in the intervention group. Of the patients, 35.4% in the control group and 76.0% in the intervention group p < 0.001 had a complete response to the antiemetic prophylaxis. The severity of acute and delayed nausea was not reduced. The global health scale and two symptom scales nausea and vomiting, appetite loss of the EORTC QLQ-C30 questionnaire were positively affected by pharmaceutical care. Patient satisfaction with information was significantly higher in the intervention group.

ConclusionsPatients with breast and ovarian cancer seem to benefit from pharmaceutical care, as suggested by improved patient-reported outcomes such as emetic episodes, quality of life, and patient satisfaction after implementation.

KeywordsBreast cancer Patient-reported outcomes Pharmaceutical care Quality of life Toxicity Supportive care Andrea Liekweg and Martina Westfeld contributed equally to this work.

Electronic supplementary materialThe online version of this article doi:10.1007-s00520-012-1385-z contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Andrea Liekweg - Martina Westfeld - Michael Braun - Oliver Zivanovic - Tania Schink - Walther Kuhn - Ulrich Jaehde

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents